EDIT News and Press, Editas Medicine Inc. From 07/26/22

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corp...

Gene-editing specialist Editas Medicine (NASDAQ: EDIT) has had a challenging 2022, even compared to the struggling stock market. The company's shares are down 35% this year and nearly 60% over the past 12 months. If the company can turn things around, its recent struggles merely rep...

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei...

Baisong Mei has joined genome editing company Editas Medicine ( NASDAQ: EDIT ) in the role SVP and Chief Medical Officer, effective immediately. Dr. Mei has over 20 years of experience in the biotech and pharmaceutical industry, serving as Senior Global Project Head in Rar...

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei wi...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks,  subscribe to his mailing list here . Oil Drops Below $10...

The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...

Gainers: MorphoSys  (MOR) +20%. NGM Biopharmaceuticals (NGM) +14%. National Vision Holdings (EYE) +10%. Editas Medicine (EDIT) +10%. Hyzon Motors  (HYZN) +5%. Losers: Outset Medical (OM) -22%. Redbox Entertainment  (RDBXW) -14%. Xperi Holding Corporation (XPER) -7%. C...

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...